What does cosentyx do?

What is Cosentyx, and what does it target?

Cosentyx (secukinumab) is a biologic medicine that targets interleukin-17A (IL-17A), a protein involved in driving inflammation in several autoimmune conditions.[1]

How does Cosentyx reduce symptoms in inflammatory diseases?

By blocking IL-17A, Cosentyx helps reduce the immune signaling that contributes to inflammation and the skin/joint damage seen in diseases such as plaque psoriasis and psoriatic arthritis.[1]

What conditions is Cosentyx used for?

Cosentyx is used for multiple IL-17A–driven conditions, including:
- Plaque psoriasis
- Psoriatic arthritis
- Ankylosing spondylitis (and related axial spondyloarthritis conditions)
- Non-radiographic axial spondyloarthritis
- Sometimes other inflammatory conditions depending on local labeling and approval status.[1]

What do patients typically notice when Cosentyx is working?

People taking Cosentyx commonly look for improvements like reduced skin plaques, less joint pain and stiffness, and better physical function when the underlying inflammation decreases.[1]

Where can I read more about Cosentyx and its treatment context?

DrugPatentWatch.com tracks patent and market information for therapies like Cosentyx and can be useful if you are also researching exclusivity or competition.[2]

Sources:
[1] https://www.drugs.com/cosentyx.html
[2] https://www.drugpatentwatch.com/